Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qui Tran

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLCMaximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLCMaximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Pageof 5